Seer Biosciences, Inc. announced that it has received $5.999999 million in funding from Maverick Ventures and other investors
January 03, 2018
Share
On January 4, 2018, Seer Biosciences, Inc. closed the transaction. The transaction included participation from 11 investors. The company has issued 6,607,201 series A preferred shares at a price of $0.9081 per share for the gross proceeds of $5,999,999.2281. The preferred shares are convertible. The preferred shares will be converted into common shares at a fixed price of $0.9081 per share. The preferred shares will entitled to receive fixed, participating and non-cumulative dividend of $0.0545 per annum. The transaction was raised at post money valuation of $27,897,223.3911. The transaction was led by Maverick Ventures with participation from other investors.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
